DE102015016801A1 - Chemotherapeutic method for the treatment of malignant tumors by "decoupling" of the oxidative phosphorylation ("Krebsatmung") in aerobic glycosylating cells (cancer cells) - Google Patents

Chemotherapeutic method for the treatment of malignant tumors by "decoupling" of the oxidative phosphorylation ("Krebsatmung") in aerobic glycosylating cells (cancer cells) Download PDF

Info

Publication number
DE102015016801A1
DE102015016801A1 DE102015016801.0A DE102015016801A DE102015016801A1 DE 102015016801 A1 DE102015016801 A1 DE 102015016801A1 DE 102015016801 A DE102015016801 A DE 102015016801A DE 102015016801 A1 DE102015016801 A1 DE 102015016801A1
Authority
DE
Germany
Prior art keywords
cells
cancer cells
decoupling
oxidative phosphorylation
glycosylating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE102015016801.0A
Other languages
German (de)
Inventor
Friedrich Windisch
Christian Windisch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE102015016801.0A priority Critical patent/DE102015016801A1/en
Publication of DE102015016801A1 publication Critical patent/DE102015016801A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Chemotherapeutisches Verfahren zur Behandlung maligner Geschwülste durch „Entkopplung” der oxidativen Phosphorylierung („Krebsatmung”) in aerob glycolysierenden Zellen (Krebszellen) a) die zellphysiologische Grundlage besteht darin, dass nach F. Windisch in aerob glycolysierenden Zellen (Krebszellen) ein autonom energie(ATP)produzierender Biomechanismus existiert („Krebsatmung” nach H. Jung), der durch „Entkopplung” der oxidativen Phosphorylierung (z. B. mit 2,4 DPN) paralysiert wird. b) die Krebszellen verfallen der Zytostase, büßen ihre Malignität ein und unterliegen einem natürlichen Alterungsprozess. Der Organismus wird nicht mit Nekrose-Toxinen belastet. c) technisches Vorgehen im Tierversuch – in diesem Falle mit einer 2,4 DNP Lösung (500 mg 2,4 DNP in 1000 ml 0,9%-iger NaCl Lösung): Subcutane Umspritzung der Tumoren, sowie orale Verabreichung der Lösung. Bei schwer zugänglichen Tumoren, wird der Wirkstoff über einen Katheter an das entartete Gewebe herangeführt. [Methode nach N. Bachynsky)Chemotherapeutic method for the treatment of malignant tumors by "decoupling" the oxidative phosphorylation ("Krebsatmung") in aerobic glycosylating cells (cancer cells) a) the cell physiological basis is that according to F. Windisch in aerobic glycosylating cells (cancer cells) an autonomous energy (ATP ), which is paralyzed by "decoupling" of the oxidative phosphorylation (eg, with 2.4 DPN). b) the cancer cells decay the cytostasis, lose their malignancy and are subject to a natural aging process. The organism is not burdened with necrosis toxins. c) Technical procedure in animal experiments - in this case with a 2.4 DNP solution (500 mg 2.4 DNP in 1000 ml 0.9% NaCl solution): Subcutaneous injection of the tumors, as well as oral administration of the solution. In difficult to reach tumors, the drug is introduced via a catheter to the degenerated tissue. [Method according to N. Bachynsky]

Description

Die zellphysiologische Grundlage besteht darin, dass nach F. Windisch in aerob glycolysierenden Zellen (Krebszellen) ein autonom energie(ATP)produzierender Biomechanismus existiert („Krebsatmung” nach H. Jung), der durch „Entkopplung” der oxidativen Phosphorylierung (z. B. mit 2,4 DNP) paralysiert wird.The cell physiological basis is that according to F. Windisch in aerobically glycosylating cells (cancer cells) an autonomous energy (ATP) -producing biomechanism exists ("cancer breathing" according to H. Jung), which by "decoupling" the oxidative phosphorylation (eg. paralyzed with 2.4 DNP).

Die Krebszellen verfallen der Zytostase, büßen ihre Malignität ein und unterliegen einem natürlichen Alterungsprozeß. Der Organismus wird nicht mit Nekrose-Toxinen belastet.

Technisches Vorgehen im Tierversuch – in diesem Falle mit einer 2,4 DNP Lösung (500 mg 2,4 DNP in 1000 ml 0,9%-iger NaCl Lösung):

Subcutane Umspritzung der Tumoren, sowie orale Verabreichung der Lösung.The cancer cells decay the cytostasis, lose their malignancy and are subject to a natural aging process. The organism is not burdened with necrosis toxins.

Technical procedure in animal experiments - in this case with a 2.4 DNP solution (500 mg 2.4 DNP in 1000 ml 0.9% NaCl solution):

Subcutaneous injection of the tumors, as well as oral administration of the solution.

Claims (1)

Chemotherapeutisches Verfahren zur Behandlung maligner Geschwülste durch „Entkopplung” der oxidativen Phosphorylierung („Krebsatmung”) in aerob glycolysierenden Zellen (Krebszellen) a) die zellphysiologische Grundlage besteht darin, dass nach F. Windisch in aerob glycolysierenden Zellen (Krebszellen) ein autonom energie(ATP)produzierender Biomechanismus existiert („Krebsatmung” nach H. Jung), der durch „Entkopplung” der oxidativen Phosphorylierung (z. B. mit 2,4 DPN) paralysiert wird. b) die Krebszellen verfallen der Zytostase, büßen ihre Malignität ein und unterliegen einem natürlichen Alterungsprozess. Der Organismus wird nicht mit Nekrose-Toxinen belastet. c) technisches Vorgehen im Tierversuch – in diesem Falle mit einer 2,4 DNP Lösung (500 mg 2,4 DNP in 1000 ml 0,9%-iger NaCl Lösung): Subcutane Umspritzung der Tumoren, sowie orale Verabreichung der Lösung. Bei schwer zugänglichen Tumoren, wird der Wirkstoff über einen Katheter an das entartete Gewebe herangeführt. [Methode nach N. Bachynsky)Chemotherapeutic method for the treatment of malignant tumors by "decoupling" of the oxidative phosphorylation ("Krebsatmung") in aerobic glycosylating cells (cancer cells) a) the cell physiological basis is that according to F. Windisch aerobically glycosylating cells (cancer cells) an autonomous energy (ATP) -producing biomechanism exists ("cancer breathing" according to H. Jung), which by "decoupling" the oxidative phosphorylation (z. B. with 2.4 DPN) is paralyzed. b) the cancer cells decay the cytostasis, lose their malignancy and are subject to a natural aging process. The organism is not burdened with necrosis toxins. c) Technical procedure in animal experiments - in this case with a 2.4 DNP solution (500 mg 2.4 DNP in 1000 ml 0.9% NaCl solution): Subcutaneous injection of the tumors, as well as oral administration of the solution. In difficult to reach tumors, the drug is introduced via a catheter to the degenerated tissue. [Method according to N. Bachynsky]
DE102015016801.0A 2015-12-23 2015-12-23 Chemotherapeutic method for the treatment of malignant tumors by "decoupling" of the oxidative phosphorylation ("Krebsatmung") in aerobic glycosylating cells (cancer cells) Ceased DE102015016801A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE102015016801.0A DE102015016801A1 (en) 2015-12-23 2015-12-23 Chemotherapeutic method for the treatment of malignant tumors by "decoupling" of the oxidative phosphorylation ("Krebsatmung") in aerobic glycosylating cells (cancer cells)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102015016801.0A DE102015016801A1 (en) 2015-12-23 2015-12-23 Chemotherapeutic method for the treatment of malignant tumors by "decoupling" of the oxidative phosphorylation ("Krebsatmung") in aerobic glycosylating cells (cancer cells)

Publications (1)

Publication Number Publication Date
DE102015016801A1 true DE102015016801A1 (en) 2017-06-29

Family

ID=59010465

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102015016801.0A Ceased DE102015016801A1 (en) 2015-12-23 2015-12-23 Chemotherapeutic method for the treatment of malignant tumors by "decoupling" of the oxidative phosphorylation ("Krebsatmung") in aerobic glycosylating cells (cancer cells)

Country Status (1)

Country Link
DE (1) DE102015016801A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150056160A1 (en) * 1998-07-27 2015-02-26 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
WO2015031756A1 (en) * 2013-08-30 2015-03-05 Yale University Novel 2,4-dinitrophenol formulations and methods using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150056160A1 (en) * 1998-07-27 2015-02-26 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
WO2015031756A1 (en) * 2013-08-30 2015-03-05 Yale University Novel 2,4-dinitrophenol formulations and methods using same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Windisch, F. [u. a.]: Involution von Walker-Karzinom und Jensen-Sarkom der Ratte durch zytostatische Antimetabolitwirkung. In: Zeitschrift für die gesamte Innere Medizin und ihre Grenzgebiete, 1957, Vol. 12, S. 615-617 *
Windisch, F. [u. a.]: Regression maligner Tumoren durch Injizierung und perorale Verabreichung von zytostatischen Antimetaboliten. In: Naturwiss., 1955, Vol. 42, S. 394-395 *

Similar Documents

Publication Publication Date Title
RU2016102158A (en) APPLICATION OF ERIBULIN AND LENVATINIB AS A COMBINED THERAPY FOR TREATMENT OF CANCER
MX2023005455A (en) Methods of treating heart failure by administering omecamtiv mecarbil.
SG10201906400SA (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EA201691420A1 (en) COMPOSITIONS OF ENOLOGY 1 (ENO1) AND THEIR APPLICATION
MX2019004586A (en) Transseptal insertion device.
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX2022000430A (en) Administration of sting agonist and checkpoint inhibitors.
ES2656913T3 (en) Endrogenin A and antineoplastic agents for the treatment of chemosensitive or chemoresistant tumors
DE102015016801A1 (en) Chemotherapeutic method for the treatment of malignant tumors by "decoupling" of the oxidative phosphorylation ("Krebsatmung") in aerobic glycosylating cells (cancer cells)
WO2021011844A3 (en) Combination cancer therapy agents and methods
CN205339754U (en) Novel insulin injection device
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
CN104207399B (en) A kind of cooling slippers with treatment beriberi
CN104547150A (en) Application of inflammation-diminishing and pain-relieving external medicine as oral agent for treating tumors and ulcerative carbuncles
CN103405542B (en) Traditional Chinese medicine for treating leucopenia after chemotherapy
Zhao et al. Simple clinical factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy in lung cancer: a pooled analysis of 70 studies
JP2017218380A5 (en)
MD1138Y (en) Method for treating chronic adnexitis
Zahalsky et al. AMNIOTIC FLUID FOR THE TREATMENT OF ERECTILE DYSFUNCTION: MP41-13
Yokota et al. Application of Salubrinal for Bone Fracture Healing
Fernandez-Miranda Metabolic syndrome and sedation: 2 case reports
Wang Good-bye, our good friend: In memory of Geoffrey Raisman
Jang et al. New Dog Model of the Intra-abdominal Hypertension and Abdominal Compartment Syndrome
Nakano Renal dysfunction: case report
Lesiak Adalimumab/infliximab/ustekinumab

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R002 Refusal decision in examination/registration proceedings
R003 Refusal decision now final